Samson Clinical Completes Enrollment for Phase III Sublingual Minoxidil Trial in Male Pattern Hair Loss
核心洞察
Samson Clinical (搜索) has completed patient enrollment for its SAM-002 Phase III trial evaluating sublingual minoxidil (搜索) for androgenetic alopecia (搜索) in men, with results expected in mid-2026.
The 24-week randomized, placebo-controlled study aims to assess the safety and efficacy of sublingual minoxidil (搜索) as a potential first new approved medication for male pattern hair loss (搜索) this century.
Rapid enrollment reflects strong unmet need among men for effective hair loss treatments without adverse effects on libido or depression warnings that affect current therapies.
Samson Clinical (搜索), an Australian pharmaceutical company, has successfully completed patient enrollment for its pivotal SAM-002 Phase III clinical trial evaluating sublingual minoxidil (搜索) in men with androgenetic alopecia (搜索) (AGA), commonly known as male pattern hair loss (搜索). The milestone positions the company to potentially deliver the first new approved medication for this condition in over two decades.
The 24-week, multicenter, randomized, placebo-controlled Phase III study enrolled participants in a 1:1 ratio to receive either sublingual minoxidil (搜索) or placebo. With recruitment now finalized, initial results are anticipated in mid-2026. The trial details are available at ClinicalTrials.gov under identifier NCT06924632.
Addressing Significant Unmet Medical Need
Male pattern hair loss (搜索) represents the leading cause of hair loss, affecting up to 80% of men during their lifetime. For many men, AGA constitutes an unwelcome change that motivates them to seek treatment options.
"The rapid enrolment is consistent with the strong unmet need among men for safe and highly effective hair loss treatments that have no undesirable impact on libido and that do not have a black box warning regarding depression and suicide," said Professor Rodney Sinclair, Founder of Samson Clinical (搜索).
The swift recruitment pace underscores the demand for innovative therapeutic approaches. "We saw this in our rapid recruitment for this trial," Professor Sinclair noted. "It's clear that many men are eager to address their hair loss and are open to innovative treatment options."
Potential First-in-Class Therapy
If successful, sublingual minoxidil (搜索) could represent a significant advancement in hair loss treatment. "This milestone brings us a major step closer to completing our clinical trial programme. If this trial is successful, sublingual minoxidil could be the first new approved medication for male pattern hair loss (搜索) this century," Professor Sinclair stated.
The sublingual formulation is designed to provide a safe, effective, convenient, and more usable alternative to existing therapies. This approach builds on Professor Sinclair's pioneering work in low-dose oral minoxidil, a term he coined in his 2018 publication on female pattern baldness treatment.
Scientific Foundation and Clinical Development
Since Professor Sinclair's original 2018 publication, over a thousand scientific articles have been published in top-tier medical journals, culminating in international consensus guidelines. This extensive body of research has established the scientific foundation for low-dose oral minoxidil therapy.
The current Phase III trial represents the culmination of Samson Clinical (搜索)'s clinical development program, building on earlier phases to evaluate both safety and efficacy parameters in the target patient population. The study's design as a randomized, placebo-controlled trial follows gold-standard methodology for regulatory approval pathways.